It was reported that everolimus (inhibitor of mTOR pathway) was effective in therapy for refractory ACTHoma with STK11 mutation resulting in stable disease for at least 6 months. The gene discussed is MTOR; the disease is ACTH-producing pituitary gland adenoma.